INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)
Photo courtesy of Amolyt Pharma

INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview. In Part 1, we discussed Dr. Sumeray's background, what hypoparathyroidism is, and its symptoms and treatments. Today, we're…

Continue Reading INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)
INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)
Photo courtesy of Amolyt Pharma

INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)

When it comes to drug development and medical research, particularly within the rare disease sphere, it is incredibly important for patients to feel involved in the process. After all, patients…

Continue Reading INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)